Volcano Reports Record Third Quarte...(expenses 61825 (4269) ...),Health
Navigation Links
Volcano Reports Record Third Quarter Revenues
Date:11/8/2007
expenses 61,825 (4,269) - 57,556
Operating loss (6,686) 4,703 - (1,983)
Interest expense (193) - - (193)
Interest and other
income, net 4,672 - - 4,672
Income (loss) before
provision for income taxes (2,207) 4,703 - 2,496
Provision for income taxes 626 - - 626
Net income (loss) $(2,833) $4,703 $- $1,870
Net income (loss) per
share - basic $(0.07) $0.12 $- $0.05
Net income (loss) per
share - diluted $(0.07) $0.11 $- $0.04
Weighted-average shares
outstanding - basic 38,368 38,368
Weighted-average shares
outstanding - diluted 38,368 41,739
Nine Months Ended September 30, 2006
Stock-based Write-off of Non-
GAAP compensation deferred debt GAAP
results expense issuance costs results
Revenues $73,517 $- $- $73,517
Cost of revenues 30,248 (239) - 30,009
Gross profit 43,269 239 - 43,508
Operating expenses:
Selling, general
and administrative 35,027 (1,680) - 33,347
Research and
development 12,835 (375) - 12,460
Amortization of
intangibles 2,332 - - 2,332
Total operating
expenses
'/>"/>
| SOURCE Volcano Corporation Copyright©2007 PR Newswire. All rights reserved |
Related medicine news :
1. Volcano Corporation Announces Proposed Public Offering of Common Stock
2. Volcano Corporation Reports Preliminary Third Quarter 2007 Revenues
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. Haemacure Reports Third Quarter 2007 Results
5. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
6. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
7. MDS Reports Third Quarter 2007 Results
8. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
11. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
Post Your Comments:
(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall/...loper, manufacturer and supplier of premium,diagno...ts dedicated to,serving the healthcare needs of wo...uarter and fiscal 2008 operating results on Tuesda...ction with the release, management will,host a con...
(Date:10/10/2008)... PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuVie... management of Trace Life Sciences Inc.,(Trace), i...cyclotron,production facilities in Denton, Texas. ... Indium-111, Iodine-123 and Thallium-201 used in,m... NuView Chairman and,CEO, stated that "We are conf...
(Date:10/10/2008)... Coach Holly Warlick Teams Up with Legal and Me...rst-Ever Cancer and Careers Seminar in,Knoxville, ...gnition of National,Breast Cancer Awareness Month,... have joined forces with YWCA Knoxville, The Welln...ocate Holly Warlick, University of Tennessee,women...
(Date:10/10/2008)... The Healthcare Technolog...Care , Exton, PA (PRWEB) ...Valley Chapters of the national Healthcare Informa...ned forces to bring regional health information te...onal conference entitled The Healthcare Technology...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2[0] Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008[0] NuView Life Sciences Inc. Assumes Management of Trace Life Sciences Inc. Radioisotope Production Facility[0] Local Experts Help Women Living and Working with Cancer Even the Score[0] HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference
...ntry reported a new suspected case of the disease ... happened hours after doctors gave the cleared a w...n Hyderabed a 48-year-old software worker was imme... from Australia via Singapore. He had symptoms of ...
...ished in the Proceedings for the 2003 Annual Meeti..., suggests that assessing leptin levels may be a m...ring body mass index and the amount of fat in a wo...east cancer are perfect, says lead author Dr Richa...
...researchers from Harvard Medical School has shown ...un over twice the risk of a stroke caused by bleed...fied a link between ischemic stroke - caused by a ...oking. The new study that covered 22,022 male US p...
...for a long time now a lot of health experts that t...ter. It has been advised we shoulddrink at least e... we areadequately hydrated. Researchers from Cente...of Nebraska have now reported that drinking other ...
Other Medicine News:(Date:10/8/2008)...ical Incorporated (Nasdaq: VICL ),today is presen...ta,demonstrating that the company,s Vaxfectin(R) a...ein-based infectious disease vaccines and,peptide-... Ph.D., Vical,s,Senior Vice President of Product D..., October 8, at the World Vaccine Congress (Lyon, ...
(Date:10/7/2008)... for detecting polyps that can be ...ct. 7 /- At the American College of,G...do (ACG 2008), renowned,gastroenterologist Douglas...tional clinical study that evaluated the efficacy ...at is designed to improve the ability,of physician...
(Date:10/7/2008)...d Immunologic Changes Induced by G...Data Indicates Potential in Treating Inflammatory ... -- Alba Therapeutics Corporation,presented result...can,College of Gastroenterology (ACG) 2008 Annual ... the first Phase IIa trial conducted in celiac dis...
(Date:10/7/2008)...ual Scientific Meeting -, ORLANDO, Fla., Oct. 7 /... Inc. (formerly Microbia, Inc.) and Forest Laborat...entation of results from a Phase,2b study assessin...s with,irritable bowel syndrome with constipation ... daily oral dosing of linaclotide, across a range ...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5MedeFile To Be Marketed in Over 100 000 Retail Outlets 22484 1MedeFile To Be Marketed in Over 100 000 Retail Outlets 22484 2MedeFile To Be Marketed in Over 100 000 Retail Outlets 22484 3MedeFile To Be Marketed in Over 100 000 Retail Outlets 22484 4Boston Scientific Welcomes Progress on Pain Care Legislation 22480 1Boston Scientific Welcomes Progress on Pain Care Legislation 22480 2Boston Scientific Welcomes Progress on Pain Care Legislation 22480 3Boston Scientific Welcomes Progress on Pain Care Legislation 22480 4Medicsight to Present at Piper Jaffray Annual Europe Conference 6145 1Medicsight to Present at Piper Jaffray Annual Europe Conference 6145 2FDA Lifts Clinical Hold on Gentas Tesetaxel a Leading Oral Taxane 2493 1FDA Lifts Clinical Hold on Gentas Tesetaxel a Leading Oral Taxane 2493 2FDA Lifts Clinical Hold on Gentas Tesetaxel a Leading Oral Taxane 2493 3FDA Lifts Clinical Hold on Gentas Tesetaxel a Leading Oral Taxane 2493 4[0] Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months[0] National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon[0] Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting[1] Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
...e 29, 2007-Preliminary results from,the immunother...ancer Center show a very good safety profile for S...evelopment have been observed,among several patien...with the monoclonal antibody against neuroblastoma...mpany,s report for,the 1st quarter 2007, all 24 pa...
...cacy trends from ongoing phase I/II trial,of oncol...n in,press conference , MARTINSRIED, Germany, June...furt, Prime Standard: MDG) announces that a case,r...s cancer killing,virus will be presented in a pres...cal Oncology. Out of more than 300 posters accepte...
Other Medicine Technology:Biotec Pharmacon Announces Preliminary Results from the,Sloan-Kettering Clinical Study 2Biotec Pharmacon Announces Preliminary Results from the,Sloan-Kettering Clinical Study 3European Society for Medical Oncology (ESMO) Presents Data from the,Clinical Trial of MediGene's Cancer-Killing Virus in Press,Conference 2Introducing the Guidant HEARTSTRING Proximal Seal System. A surgically intuitive system that meets the challenge of clampless hemostasis with a design that is elegant in its simplicity and profound i
...ystem, developed by Given Imaging of Israel, is a ...ape. Weighing in at only four grams, it contains a...ry and radio transmitter coated by a smooth biocom...ymes. Internal gastric images are transmitted to a...
CO2 TMR technology is an effective angina relief therapy for diffuse vessels with poor targets. Because it is easily moved between surgical suites, the CO2 Heart Laser 2 enables the surgeon to make t
TSH EIA Thyroid Function 025-BC-1001
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |